Does genetic susceptibility increase risk for neurocognitive decline among patients with acute lymphoblastic leukemia?

Research output: Contribution to journalReview article

1 Citation (Scopus)
Original languageEnglish (US)
Pages (from-to)1855-1858
Number of pages4
JournalFuture Oncology
Volume11
Issue number13
DOIs
StatePublished - Jul 1 2015

Fingerprint

Pharmaceutical Economics
Pharmacogenetics
Genetic Predisposition to Disease
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Methotrexate
Oxidative Stress
Neurocognitive Disorders

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Keywords

  • acute lymphoblastic leukemia
  • methotrexate
  • neurocognitive function
  • oxidative stress
  • pharmacogenomics

Cite this

@article{106870cc78c84800b376b89aabf65568,
title = "Does genetic susceptibility increase risk for neurocognitive decline among patients with acute lymphoblastic leukemia?",
keywords = "acute lymphoblastic leukemia, methotrexate, neurocognitive function, oxidative stress, pharmacogenomics",
author = "Peter Cole",
year = "2015",
month = "7",
day = "1",
doi = "10.2217/fon.15.117",
language = "English (US)",
volume = "11",
pages = "1855--1858",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "13",

}

Does genetic susceptibility increase risk for neurocognitive decline among patients with acute lymphoblastic leukemia? / Cole, Peter.

In: Future Oncology, Vol. 11, No. 13, 01.07.2015, p. 1855-1858.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Does genetic susceptibility increase risk for neurocognitive decline among patients with acute lymphoblastic leukemia?

AU - Cole, Peter

PY - 2015/7/1

Y1 - 2015/7/1

KW - acute lymphoblastic leukemia

KW - methotrexate

KW - neurocognitive function

KW - oxidative stress

KW - pharmacogenomics

UR - http://www.scopus.com/inward/record.url?scp=84936929939&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84936929939&partnerID=8YFLogxK

U2 - 10.2217/fon.15.117

DO - 10.2217/fon.15.117

M3 - Review article

VL - 11

SP - 1855

EP - 1858

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 13

ER -